Back to Search
Start Over
Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports.
- Source :
- Thoracic Cancer; Jan2014, Vol. 5 Issue 1, p38-42, 5p
- Publication Year :
- 2014
-
Abstract
- Background Epidermal growth factor-tyrosine kinase inhibitors ( EGFR- TKIs) are one of the effective medicines in advanced lung adenocarcinoma leptomeningeal metastasis ( LM) treatment in recent years. Methods This paper reports two cases of advanced lung adenocarcinoma with exon-EGFR19 mutation. LM occurred during gefitinib treatment with an extracranial condition under control. Later, erlotinib was adopted with a recurrent response. Results The progression free survival of both patients was over six months and their LM was under control for six and a half and nine months, respectively. LM may be sensitive on different levels to different EGFR- TKIs. Conclusion Erlotinib can be used to replace gefitinib if intracranial tumor progress occurs during gefitinib treatment. However, our conclusion still needs to be proven by further clinical research. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 17597706
- Volume :
- 5
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Thoracic Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 93393332
- Full Text :
- https://doi.org/10.1111/1759-7714.12049